Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Clinical trial NCT03178851 · COMPLETED
Trial details
- NCT number
- NCT03178851
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-20
- Primary completion
- 2019-05-29
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.